Madrigal Pharmaceuticals-Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates

Madrigal (MDGL) came out with a quarterly loss of $3.32 per share versus the Zacks Consensus Estimate of a loss of$ 3.62. This compares to loss of $7.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.29%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 4.12 per share when it actually produced a loss of $2.71, delivering a surprise of 34.22%.Over the last four quarters, the company ha ...